NAVAN Technologies, Inc. says it has closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi Ventures, and other institutional and private investors. The privately held biotechnology company develops its non-viral NanoStraw platform to enable next-generation cell and gene therapies; the platform is based on technology exclusively licensed from Stanford University.
Navan Technologies, a developer of Stanford-licensed drug-release technology, receives seed funding, with Amgen among its investors. The company hopes its nanoinjection technique will enable more cell and gene therapies to be produced at scale.
South San Francisco-based NAVAN Technologies, a biotechnology company, secures an undisclosed amount of seed funding. Investors include Amgen Ventures, High-Tech Gründerfonds and Hemi Ventures.
NAVAN Technologies, Inc. closes a seed funding round. The privately held biotechnology company enables the development of next-generation cell and gene therapies.
